{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:01:37Z","timestamp":1790791297710,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1303,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer AB"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition caused by deposition of transthyretin amyloid fibrils in the heart and is associated with poor quality of life and a shortened lifespan. This study aimed to describe the prevalence, clinical characteristics, and mortality of patients with ATTR-CM, using multiple national health registers in Denmark, Finland, Norway, and Sweden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Transthyretin amyloid cardiomyopathy patients were identified during 2008\u20132018 using a combination of diagnosis codes for amyloidosis and heart disease and were matched to patients with non-ATTR heart failure (HF). An identical study design was used in each country to facilitate comparison and aggregation of results. A total of 1930 ATTR-CM patients were identified from national health registers in the four countries. In 2018, prevalence of ATTR-CM per 100 000 inhabitants ranged from 1.4 in Denmark to 5.0 in Sweden; a steep increase over time was observed in Sweden and Norway. Median survival from diagnosis was 30 months for ATTR-CM patients and 67 months for matched HF patients. Survival was significantly lower for female than for male ATTR-CM patients (median survival: 22 and 36 months), while no significant difference was observed in the HF cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides the first nationwide estimates of the prevalence, clinical characteristics, and mortality of patients with ATTR-CM, using identical study design across several countries. Findings corroborate previous case series showing high mortality in ATTR-CM, two-fold higher than for other HF patients and higher in women than men, highlighting the need for more precise and early diagnosis to reduce the disease burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13961","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T01:39:10Z","timestamp":1652405950000},"page":"2528-2537","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Prevalence, Characteristics, and Mortality of Patients with Transthyretin Amyloid Cardiomyopathy in the Nordic Countries"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5776-6600","authenticated-orcid":false,"given":"Rosa","family":"Lauppe","sequence":"first","affiliation":[{"name":"Quantify Research , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Liseth Hansen","sequence":"additional","affiliation":[{"name":"Quantify Research , Stockholm ,","place":["Sweden"]},{"name":"Institute of Health and Society, Faculty of Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fornwall","sequence":"additional","affiliation":[{"name":"Quantify Research , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Johansson","sequence":"additional","affiliation":[{"name":"Pfizer AB , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Rozenbaum","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. , Capelle a\/d IJssel ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Mette","family":"Strand","sequence":"additional","affiliation":[{"name":"Pfizer Denmark ApS , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja","family":"V\u00e4kev\u00e4inen","sequence":"additional","affiliation":[{"name":"Pfizer Oy , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Kuusisto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Research, Kuopio University Hospital and University of Eastern Finland , Kuopio ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Gude","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Gustav","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Clinical Sciences, Lund University and Sk\u00e5ne University Hospital , Lund ,","place":["Sweden"]},{"name":"The Wallenberg Laboratory\/Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University and Sahlgrenska University Hospital , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology , Rigshospitalet, Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"2026012114151526800_ehf213961-bib-0001","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac amyloidosis: Overlooked, underappreciated, and treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu Rev Med"},{"key":"2026012114151526800_ehf213961-bib-0002","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2026012114151526800_ehf213961-bib-0003","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012114151526800_ehf213961-bib-0004","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012114151526800_ehf213961-bib-0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: Clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026012114151526800_ehf213961-bib-0006","article-title":"Two decades of cardiac amyloidosis: A Danish Nationwide study","author":"Westin","year":"2021","journal-title":"JACC: CardioOncology"},{"key":"2026012114151526800_ehf213961-bib-0007","volume-title":"Genealogic studies of the Swedish hereditary transthyretin amyloidosis (ATTR V30M) population: differences in age at onset within the population","author":"Norgren","year":"2014"},{"key":"2026012114151526800_ehf213961-bib-0008","first-page":"1","article-title":"Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy: A systematic review and Meta-analysis","volume":"10","author":"Kroi","year":"2020","journal-title":"Cardiol Ther"},{"key":"2026012114151526800_ehf213961-bib-0009","first-page":"391","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: An insight through the transthyretin amyloidosis outcomes survey (THAOS)","volume":"1","author":"Damy","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012114151526800_ehf213961-bib-0010","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001755","article-title":"Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden","volume":"8","author":"Lauppe","year":"2021","journal-title":"Open Heart"},{"key":"2026012114151526800_ehf213961-bib-0011","article-title":"Transthyretin amyloid cardiomyopathy in women: Frequency, characteristics, and diagnostic challenges","author":"Bruno","year":"2020","journal-title":"Heart Fail Rev"},{"key":"2026012114151526800_ehf213961-bib-0012","doi-asserted-by":"crossref","first-page":"S498","DOI":"10.1016\/j.jval.2020.08.558","article-title":"PCV67 epidemiology of transthyretin amyloid cardiomyopathy (ATTR-CM) in France: EPACT, a study based on the French Nationwide claims database Snds","volume":"23","author":"Damy","year":"2020","journal-title":"Value Health"},{"key":"2026012114151526800_ehf213961-bib-0013","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026012114151526800_ehf213961-bib-0014","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40119-019-0142-5","article-title":"Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan","volume":"8","author":"Winburn","year":"2019","journal-title":"Cardiol Ther."},{"key":"2026012114151526800_ehf213961-bib-0015","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2021"},{"key":"2026012114151526800_ehf213961-bib-0016","volume-title":"Stata Statistical Software: Release 16","author":"StataCorp","year":"2021"},{"key":"2026012114151526800_ehf213961-bib-0017","volume-title":"The Epidemiology and Outcomes of Critical Illness in Manitoba","author":"Garland","year":"2012"},{"key":"2026012114151526800_ehf213961-bib-0018","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026012114151526800_ehf213961-bib-0019","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmg.31.5.351","article-title":"Geographical distribution of TTR met30 carriers in northern Sweden: Discrepancy between carrier frequency and prevalence rate","volume":"31","author":"Holmgren","year":"1994","journal-title":"J Med Genet"},{"key":"2026012114151526800_ehf213961-bib-0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/13506120600876849","article-title":"Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy","volume":"13","author":"Suhr","year":"2006","journal-title":"Amyloid"},{"key":"2026012114151526800_ehf213961-bib-0021","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/ctr.12633","article-title":"Outcome in patients treated with isolated liver transplantation for familial transthyretin amyloidosis to prevent cardiomyopathy","volume":"29","author":"Nelson","year":"2015","journal-title":"Clin Transplant"},{"key":"2026012114151526800_ehf213961-bib-0022","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1016\/S2468-2667(19)30224-5","article-title":"Life expectancy and disease burden in the Nordic countries: Results from the global burden of diseases, injuries, and risk factors study 2017","volume":"4","author":"Knudsen","year":"2019","journal-title":"Lancet Public Health"},{"key":"2026012114151526800_ehf213961-bib-0023","doi-asserted-by":"crossref","volume-title":"Baseline characteristics of patients with transthyretin amyloid cardiomyopathy enrolled in a tafamidis expanded access programme","author":"Rozenbaum","DOI":"10.1093\/eurheartj\/ehab724.1799"},{"key":"2026012114151526800_ehf213961-bib-0024","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab724.1800","volume-title":"Demographic Characteristics of the 1902 Transthyretin Amyloid Cardiomyopathy Patients Treated By Tafamidis Through the French Early Access Program","author":"Lairez","year":"2021"},{"key":"2026012114151526800_ehf213961-bib-0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-020-1300-5","article-title":"Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study","volume":"15","author":"Schmidt","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2026012114151526800_ehf213961-bib-0026","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and Management of Cardiac Amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"2026012114151526800_ehf213961-bib-0027","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz748.0011","article-title":"Interim analysis of data from a long-term, extension trial of tafamidis meglumine in patients with transthyretin amyloid cardiomyopathy","volume":"40","author":"Elliott","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012114151526800_ehf213961-bib-0028","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/eurjhf\/hfq121","article-title":"Epidemiology and clinical course of heart failure with preserved ejection fraction","volume":"13","author":"Lam","year":"2011","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13961","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13961","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/4\/2528\/65348979\/eschf_9_4_2528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/4\/2528\/65348979\/eschf_9_4_2528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:18:11Z","timestamp":1769023091000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/4\/2528\/8322994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,5,12]]},"published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13961","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8]]},"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"2022-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}